Welcome to our dedicated page for Pyxis Oncology SEC filings (Ticker: PYXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pyxis Oncology, Inc. filings document a clinical-stage oncology company developing MICVO, an investigational antibody-drug conjugate for difficult-to-treat cancers. Its 8-K reports cover financial results, corporate updates, Regulation FD presentations, clinical data disclosures, and trial-related updates for MICVO in recurrent or metastatic head and neck squamous cell carcinoma and other advanced solid tumors.
The company’s regulatory record also includes proxy materials for annual meeting matters, director elections, governance proposals, executive transitions, employment and separation arrangements, equity compensation matters, and emerging growth company status. These filings describe Pyxis Oncology’s public-company governance, program disclosures, capital-related arrangements, and risk-linked clinical development reporting.
Pyxis Oncology, Inc. held its Annual Meeting of Stockholders in virtual format on June 15, 2026. As of the April 20, 2026 record date, 62,855,464 shares of common stock were outstanding and entitled to vote. A quorum was present, with 47,302,035 shares represented virtually, in person or by proxy.
Stockholders elected three Class II directors—Thomas Civik, Freda Lewis-Hall, M.D., and Michael A. Metzger—to serve until the 2029 annual meeting and until their successors are elected and qualified. Support levels varied by nominee, with for votes ranging from 19,188,755 to 27,341,415.
Stockholders also ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 46,203,257 votes for, 1,076,997 against and 21,781 abstentions.
Pyxis Oncology reported a net loss of $23.3 million for the quarter ended March 31, 2026, slightly higher than the $21.2 million loss a year earlier, as it increased spending on its lead cancer drug candidate MICVO.
Research and development expenses rose to $20.0 million, driven mainly by higher clinical trial and preclinical costs for MICVO monotherapy and combination studies. General and administrative expenses fell to $4.4 million, largely due to lower stock-based compensation.
Pyxis ended the quarter with $41.0 million in cash, cash equivalents and marketable debt securities and an accumulated deficit of $466.4 million. Management states there is substantial doubt about the company’s ability to continue as a going concern beyond the next 12 months without additional financing, despite having an effective $350.0 million shelf registration and $150.0 million at-the-market capacity.
Pyxis Oncology, Inc. reported first quarter 2026 results and highlighted progress in its lead antibody-drug conjugate, micvotabart pelidotin (MICVO), for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Updated MICVO Phase 1 monotherapy data in 2L+ R/M HNSCC are planned for mid‑2026, focusing on patients treated at or below a dose cap introduced in December 2025, while updated Phase 1/2 combination data with KEYTRUDA in 1L R/M HNSCC are expected in the second half of 2026. The company also presented supportive preclinical data at the 2026 AACR meeting and completed target enrollment in the Phase 1 monotherapy dose expansion study.
Financially, Pyxis Oncology reported a Q1 2026 net loss of $23.3 million, or ($0.37) per share, compared with a net loss of $21.2 million, or ($0.35) per share, a year earlier. Research and development expenses rose to $20.0 million, while general and administrative expenses declined to $4.4 million. The company ended March 31, 2026 with $42.5 million in cash, cash equivalents, restricted cash, and short‑term investments and expects this to fund operations into the fourth quarter of 2026.
Pyxis Oncology is asking stockholders to vote at its 2026 virtual annual meeting on June 15, 2026. The proxy seeks approval to elect three Class II directors (Thomas Civik, Freda Lewis‑Hall, M.D., and Michael A. Metzger) and to ratify Ernst & Young LLP as auditor for 2026.
Stockholders of record as of April 20, 2026, holding 62,855,464 outstanding common shares in aggregate, are entitled to vote online, by phone, mail, or during the live webcast after registering at proxydocs.com/PYXS.
Pyxis Oncology, Inc. filed an amendment to outline the separation terms for Lara Sullivan, M.D., whose service as Chief Executive Officer and principal executive officer ended earlier in 2026. The filing also notes that she resigned from the Board of Directors on April 29, 2026, and that her resignation was not due to any dispute or disagreement over the company’s operations or policies.
Under a Separation and General Release Agreement effective April 29, 2026, Dr. Sullivan will receive her existing salary for 18 months and may continue health coverage for up to 12 months. All of her unvested restricted stock units and stock options will vest, and the period to exercise her stock options is extended to December 31, 2030. The agreement includes a one-year post-separation non-solicitation covenant for Dr. Sullivan and a one-year mutual non-disparagement covenant.
Pyxis Oncology director Jakob Dupont received a new stock option grant. The award covers 45,867 options to buy Common Stock at an exercise price of $1.36 per share, expiring on March 24, 2036. All of these options vest 100% on the first anniversary of the grant date, contingent on his continued service. Following this grant, Dupont holds 45,867 derivative securities, reflecting a routine, compensation-related equity award rather than an open‑market trade.
Pyxis Oncology, Inc. reported that principal financial and accounting officer Jitendra Wadhane received new equity compensation awards. He was granted a stock option for 262,635 shares of common stock at an exercise price of $1.36 per share, expiring on March 24, 2036. He also received 109,461 shares of common stock in the form of restricted stock units at no cost.
The restricted stock units vest 25% on March 31, 2026, then in 36 substantially equal monthly installments, subject to continued employment. The stock option vests 25% on the first anniversary of March 24, 2026, with the remainder vesting in 36 equal monthly installments on continued employment. Following these awards, his directly held common stock position is 512,882 shares.
Pyxis Oncology, Inc. reported that director John L. Flavin received a grant of stock options covering 45,867 shares of common stock. The options have an exercise price of $1.36 per share and expire on March 24, 2036. According to the terms, 100% of these options vest on the first anniversary of the grant date, subject to his continued service, and following this grant he holds 45,867 derivative securities directly.
Pyxis Oncology director Michael A. Metzger received a grant of 45,867 stock options for Common Stock. The options have an exercise price of $1.3600 per share and expire on March 24, 2036. All 45,867 options vest 100% on the first anniversary of the grant date, contingent on his continued service.
Following this award, Metzger holds 45,867 options directly, and no open-market purchases or sales were reported in this filing.